trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs

Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both diastereomers of the fluorocyclopropyl analog of cabozantinib, a c-Met and VEGFR-2 inhibitor used as a first-line treatment for thyroid cancer and as...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters Vol. 11; no. 11; pp. 2146 - 2150
Main Authors: Veliks, Janis, Videja, Melita, Kinens, Artis, Bobrovs, Raitis, Priede, Martins, Kuka, Janis
Format: Journal Article
Language:English
Published: WASHINGTON Amer Chemical Soc 12.11.2020
Subjects:
ISSN:1948-5875, 1948-5875
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both diastereomers of the fluorocyclopropyl analog of cabozantinib, a c-Met and VEGFR-2 inhibitor used as a first-line treatment for thyroid cancer and as a second-line treatment for renal cell carcinoma. Despite some known potent examples, there are only a few drug molecules that contain fluorocyclopropane moieties. Herein, we present a case study in which the monofluoro analog of a known cyclopropane-containing drug molecule displays an improved in vitro profile compared to the parent nonfluorinated structure. The fluorocyclopropane moiety may offer valuable fine-tuning options for lead optimization in drug discovery.
AbstractList Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both diastereomers of the fluorocyclopropyl analog of cabozantinib, a c-Met and VEGFR-2 inhibitor used as a first-line treatment for thyroid cancer and as a second-line treatment for renal cell carcinoma. Despite some known potent examples, there are only a few drug molecules that contain fluorocyclopropane moieties. Herein, we present a case study in which the monofluoro analog of a known cyclopropane-containing drug molecule displays an improved in vitro profile compared to the parent nonfluorinated structure. The fluorocyclopropane moiety may offer valuable fine-tuning options for lead optimization in drug discovery.Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both diastereomers of the fluorocyclopropyl analog of cabozantinib, a c-Met and VEGFR-2 inhibitor used as a first-line treatment for thyroid cancer and as a second-line treatment for renal cell carcinoma. Despite some known potent examples, there are only a few drug molecules that contain fluorocyclopropane moieties. Herein, we present a case study in which the monofluoro analog of a known cyclopropane-containing drug molecule displays an improved in vitro profile compared to the parent nonfluorinated structure. The fluorocyclopropane moiety may offer valuable fine-tuning options for lead optimization in drug discovery.
Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both diastereomers of the fluorocyclopropyl analog of cabozantinib, a c-Met and VEGFR-2 inhibitor used as a first-line treatment for thyroid cancer and as a second-line treatment for renal cell carcinoma. Despite some known potent examples, there are only a few drug molecules that contain fluorocyclopropane moieties. Herein, we present a case study in which the monofluoro analog of a known cyclopropane-containing drug molecule displays an improved in vitro profile compared to the parent nonfluorinated structure. The fluorocyclopropane moiety may offer valuable fine-tuning options for lead optimization in drug discovery.
Author Kinens, Artis
Bobrovs, Raitis
Veliks, Janis
Videja, Melita
Priede, Martins
Kuka, Janis
Author_xml – sequence: 1
  givenname: Janis
  orcidid: 0000-0003-0955-8257
  surname: Veliks
  fullname: Veliks, Janis
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
– sequence: 2
  givenname: Melita
  surname: Videja
  fullname: Videja, Melita
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
– sequence: 3
  givenname: Artis
  orcidid: 0000-0003-1992-525X
  surname: Kinens
  fullname: Kinens, Artis
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
– sequence: 4
  givenname: Raitis
  orcidid: 0000-0002-0221-8658
  surname: Bobrovs
  fullname: Bobrovs, Raitis
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
– sequence: 5
  givenname: Martins
  orcidid: 0000-0002-9655-8345
  surname: Priede
  fullname: Priede, Martins
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
– sequence: 6
  givenname: Janis
  orcidid: 0000-0003-0955-8257
  surname: Kuka
  fullname: Kuka, Janis
  email: janis.veliks@osi.lv
  organization: Latvian Inst Organ Synth, LV-1006 Riga, Latvia
BookMark eNqNkM1LAzEQxYNUrFb_BclRkNVJ9ivxJmv9AMGDei5JdtZGskndpEr9612sgkdP82De7zFvDsjEB4-EHDM4Y8DZuTKxx9YssXeY0hkYAM5hh-wzWYisFHU5-aOn5CDGV4BK1jXskWmec1YIzvdJnwblY3bt1mGwHum869Akaj1tNsaF1RBWyuMFvbIqJhwwRHSjwb4jfdz4tMRoIw0d_Q4I5pfZONooHT6VT9ZbTS-9cuElHpLdTrmIRz9zRp6v50_NbXb_cHPXXN5nqgRImTYceM2wZLoyWqi8yjWDStS8YK2smOjytq2kVNJwOW5bXXd5IUSnmB45wWfkZJs73vK2xpgWvY0GnRu7hHVc8KLKQcpyfOWMiK31A3XoorHoDS5Wg-3VsFkAQCl5XRRiVIw1Nqlkg2_C2qcRPf0_yr8AZi6G3w
CitedBy_id crossref_primary_10_3390_molecules28155785
crossref_primary_10_1002_chem_202301851
Cites_doi 10.1158/0008-5472.CAN-08-4889
10.1002/ejoc.201701030
10.1016/j.ejmech.2015.12.016
10.1039/c9cp05009d
10.1002/chem.201900349
10.1039/b610213c
10.1002/chem.201901840
10.1016/j.bmc.2005.01.043
10.1016/j.bioorg.2019.04.010
10.1021/acsmedchemlett.9b00035
10.1021/acscatal.9b00354
10.1016/j.cclet.2020.03.050
10.1039/c9ob02712b
10.1158/1535-7163.MCT-11-0264
10.1021/ja402393w
10.1021/cr4002879
10.1039/c6cs00351f
10.1002/chem.201202831
10.1055/s-0035-1560557
10.1021/acs.orglett.9b02867
10.1021/acs.jmedchem.7b01788
10.1002/ijch.201600038
10.1016/j.jhep.2004.04.013
10.1634/theoncologist.2017-0335
10.1021/acs.jmedchem.6b00472
10.1021/jm201330u
10.15586/jkcvhl.2018.109
ContentType Journal Article
DBID 17B
1KM
AOWDO
BLEPL
DTL
EGQ
7X8
DOI 10.1021/acsmedchemlett.0c00220
DatabaseName Web of Knowledge
Index Chemicus
Web of Science - Science Citation Index Expanded - 2020
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
MEDLINE - Academic
DatabaseTitle Web of Science
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Web of Science
Database_xml – sequence: 1
  dbid: 1KM
  name: Index Chemicus
  url: https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1948-5875
EndPage 2150
ExternalDocumentID 000592744800011
GrantInformation_xml – fundername: ERDF project
  grantid: 1.1.1.5/17/A/003
GroupedDBID ---
17B
1KM
53G
55A
5VS
7~N
AABXI
ABBLG
ABJNI
ABLBI
ABMVS
ABQRX
ABUCX
ACGFO
ACGFS
ACS
ADBBV
ADHLV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQSVZ
BAANH
BAWUL
BLEPL
CUPRZ
DIK
DTL
EBS
ED~
F5P
GGK
GNL
GROUPED_WOS_WEB_OF_SCIENCE
GX1
HYE
IH9
JG~
OK1
P2P
RNS
ROL
RPM
UI2
VF5
VG9
W1F
XKZ
7X8
ID FETCH-LOGICAL-a500t-bc20271e51b6cb8a363b10687241d9618f3dd699a9c29a36db7f3488fa1b27182
IEDL.DBID 7X8
ISICitedReferencesCount 7
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000592744800011
ISSN 1948-5875
IngestDate Thu Oct 02 10:57:57 EDT 2025
Fri Dec 05 22:47:27 EST 2025
Tue Sep 09 07:33:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords c-Met kinase inhibitors
fluorocyclopropane
VEGFR-2 kinase inhibitors
anticancer
cabozantinib
Language English
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a500t-bc20271e51b6cb8a363b10687241d9618f3dd699a9c29a36db7f3488fa1b27182
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9655-8345
0000-0003-0955-8257
0000-0003-1992-525X
0000-0002-0221-8658
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/7667865
PMID 33214822
PQID 2463099510
PQPubID 23479
PageCount 5
ParticipantIDs webofscience_primary_000592744800011CitationCount
proquest_miscellaneous_2463099510
webofscience_primary_000592744800011
PublicationCentury 2000
PublicationDate 2020-11-12
PublicationDateYYYYMMDD 2020-11-12
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-12
  day: 12
PublicationDecade 2020
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
PublicationTitle ACS medicinal chemistry letters
PublicationTitleAbbrev ACS MED CHEM LETT
PublicationYear 2020
Publisher Amer Chemical Soc
Publisher_xml – name: Amer Chemical Soc
References Wei, DS (WOS:000475378400011) 2019; 88
Talele, TT (WOS:000385607100004) 2016; 59
Veliks, J (WOS:000461713000013) 2019; 25
(000592744800011.20) 1000
Chawner, SJ (WOS:000410792200004) 2017; 2017
Thiehoff, C (WOS:000394572500011) 2017; 57
Beaulieu, LPB (WOS:000319856700008) 2013; 135
Norman, MH (WOS:000301170000007) 2012; 55
Schmidinger, M (WOS:000427020800007) 2018; 23
Mei, HB (WOS:000476851600001) 2019; 25
Jiang, BA (WOS:000181302800040) 2003
KIMURA, Y (WOS:A1994PJ90900019) 1994; 37
Liu, CJ (WOS:000461537500028) 2019; 10
Kazia, AK (WOS:000517113000009) 2020; 18
Díaz, N (WOS:000506841300038) 2019; 21
Prakash, GKS (WOS:000252989500009) 2008; 10
Ye, S (WOS:000227891000015) 2005; 13
Zhang, J (WOS:000369191800044) 2016; 108
Wang, SY (WOS:000223455500012) 2004; 41
Ni, CF (WOS:000385181300001) 2016; 45
Mei, HB (WOS:000582384200040) 2020; 31
David, E (WOS:000311111900002) 2012; 18
Yakes, FM (WOS:000298344400009) 2011; 10
Purser, S (WOS:000252411800007) 2008; 37
Wang, J (WOS:000332144700009) 2014; 114
Melngaile, R (WOS:000485089300118) 2019; 21
Pons, A (WOS:000460600600091) 2019; 9
Pons, A (WOS:000389329500009) 2016; 48
Meanwell, NA (WOS:000440521300004) 2018; 61
Del Vecchio, SJ (WOS:000452488400001) 2018; 5
Qian, F (WOS:000270935500016) 2009; 69
BURGESS, K (WOS:A1995QU49100006) 1995; 36
References_xml – volume: 69
  start-page: 8009
  year: 2009
  ident: WOS:000270935500016
  article-title: Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-08-4889
– volume: 2017
  start-page: 5015
  year: 2017
  ident: WOS:000410792200004
  article-title: Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide
  publication-title: EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
  doi: 10.1002/ejoc.201701030
– volume: 108
  start-page: 495
  year: 2016
  ident: WOS:000369191800044
  article-title: Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
  publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1016/j.ejmech.2015.12.016
– volume: 21
  start-page: 25258
  year: 2019
  ident: WOS:000506841300038
  article-title: Fluorine conformational effects characterized by energy decomposition analysis
  publication-title: PHYSICAL CHEMISTRY CHEMICAL PHYSICS
  doi: 10.1039/c9cp05009d
– year: 1000
  ident: 000592744800011.20
  article-title: C-met Modulators and Methods of Use
– volume: 25
  start-page: 3786
  year: 2019
  ident: WOS:000461713000013
  article-title: Fluoromethylene Transfer from Diarylfluoromethylsulfonium Salts: Synthesis of Fluorinated Epoxides
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.201900349
– volume: 37
  start-page: 320
  year: 2008
  ident: WOS:000252411800007
  article-title: Fluorine in medicinal chemistry
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/b610213c
– volume: 25
  start-page: 11797
  year: 2019
  ident: WOS:000476851600001
  article-title: Fluorine-Containing Drugs Approved by the FDA in 2018
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.201901840
– volume: 13
  start-page: 2489
  year: 2005
  ident: WOS:000227891000015
  article-title: Fluorinated phenylcyclopropylamines. Part 4: Effects of aryl substituents and stereochemistry on the inhibition of monoamine oxidases by 1-aryl-2-fluoro-cyclopropylamines
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY
  doi: 10.1016/j.bmc.2005.01.043
– volume: 88
  start-page: ARTN 102916
  year: 2019
  ident: WOS:000475378400011
  article-title: Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2
  publication-title: BIOORGANIC CHEMISTRY
  doi: 10.1016/j.bioorg.2019.04.010
– volume: 10
  start-page: 383
  year: 2019
  ident: WOS:000461537500028
  article-title: Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors
  publication-title: ACS MEDICINAL CHEMISTRY LETTERS
  doi: 10.1021/acsmedchemlett.9b00035
– volume: 9
  start-page: 2594
  year: 2019
  ident: WOS:000460600600091
  article-title: Catalytic Enantioselective Cyclopropanation of α-Fluoroacrylates: An Experimental and Theoretical Study
  publication-title: ACS CATALYSIS
  doi: 10.1021/acscatal.9b00354
– volume: 31
  start-page: 2401
  year: 2020
  ident: WOS:000582384200040
  article-title: Fluorine-containing drugs approved by the FDA in 2019
  publication-title: CHINESE CHEMICAL LETTERS
  doi: 10.1016/j.cclet.2020.03.050
– volume: 18
  start-page: 1384
  year: 2020
  ident: WOS:000517113000009
  article-title: Johnson-Corey-Chaykovsky fluorocyclopropanation of double activated alkenes: scope and limitations
  publication-title: ORGANIC & BIOMOLECULAR CHEMISTRY
  doi: 10.1039/c9ob02712b
– volume: 10
  start-page: 2298
  year: 2011
  ident: WOS:000298344400009
  article-title: Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-11-0264
– volume: 135
  start-page: 7819
  year: 2013
  ident: WOS:000319856700008
  article-title: Highly Enantioselective Simmons-Smith Fluorocyclopropanation of Allylic Alcohols via the Halogen Scrambling Strategy of Zinc Carbenoids
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
  doi: 10.1021/ja402393w
– volume: 114
  start-page: 2432
  year: 2014
  ident: WOS:000332144700009
  article-title: Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001-2011)
  publication-title: CHEMICAL REVIEWS
  doi: 10.1021/cr4002879
– volume: 37
  start-page: 3344
  year: 1994
  ident: WOS:A1994PJ90900019
  article-title: (FLUOROCYCLOPROPYL)QUINOLONES .2. SYNTHESIS AND STEREOCHEMICAL STRUCTURE-ACTIVITY-RELATIONSHIPS OF CHIRAL 7-(7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-1-(2-FLUOROCYCLOPROPYL)QUINOLONE ANTIBACTERIAL AGENTS
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
– volume: 45
  start-page: 5441
  year: 2016
  ident: WOS:000385181300001
  article-title: The unique fluorine effects in organic reactions: recent facts and insights into fluoroalkylations
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/c6cs00351f
– volume: 18
  start-page: 14904
  year: 2012
  ident: WOS:000311111900002
  article-title: Syntheses and Applications of Monofluorinated Cyclopropanes
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.201202831
– volume: 48
  start-page: 4060
  year: 2016
  ident: WOS:000389329500009
  article-title: Synthesis and Applications of Fluorocyclopropanes
  publication-title: SYNTHESIS-STUTTGART
  doi: 10.1055/s-0035-1560557
– volume: 21
  start-page: 7174
  year: 2019
  ident: WOS:000485089300118
  article-title: Diastereoselective Monofluorocyclopropanation Using Fluoromethylsulfonium Salts
  publication-title: ORGANIC LETTERS
  doi: 10.1021/acs.orglett.9b02867
– start-page: 536
  year: 2003
  ident: WOS:000181302800040
  article-title: A convenient stereoselective synthesis of trifluoromethyl-substituted polyfunctionalized cyclopropane:: synthesis of (±)-trans-trifluoronorcoronamic acid
  publication-title: CHEMICAL COMMUNICATIONS
– volume: 61
  start-page: 5822
  year: 2018
  ident: WOS:000440521300004
  article-title: Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.7b01788
– volume: 57
  start-page: 92
  year: 2017
  ident: WOS:000394572500011
  article-title: The Fluorine Gauche Effect: A Brief History
  publication-title: ISRAEL JOURNAL OF CHEMISTRY
  doi: 10.1002/ijch.201600038
– volume: 41
  start-page: 267
  year: 2004
  ident: WOS:000223455500012
  article-title: SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells
  publication-title: JOURNAL OF HEPATOLOGY
  doi: 10.1016/j.jhep.2004.04.013
– volume: 23
  start-page: 306
  year: 2018
  ident: WOS:000427020800007
  article-title: Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
  publication-title: ONCOLOGIST
  doi: 10.1634/theoncologist.2017-0335
– volume: 59
  start-page: 8712
  year: 2016
  ident: WOS:000385607100004
  article-title: The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.6b00472
– volume: 55
  start-page: 1858
  year: 2012
  ident: WOS:000301170000007
  article-title: Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm201330u
– volume: 10
  start-page: 557
  year: 2008
  ident: WOS:000252989500009
  article-title: Direct electrophilic monofluoromethylation
  publication-title: ORGANIC LETTERS
– volume: 5
  start-page: 1
  year: 2018
  ident: WOS:000452488400001
  article-title: Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
  publication-title: JOURNAL OF KIDNEY CANCER AND VHL
  doi: 10.15586/jkcvhl.2018.109
– volume: 36
  start-page: 2725
  year: 1995
  ident: WOS:A1995QU49100006
  article-title: PRACTICAL ASYMMETRIC SYNTHESES OF ALL 4 2,3-METHANOLEUCINE STEREOISOMERS
  publication-title: TETRAHEDRON LETTERS
SSID ssj0069770
Score 2.2683647
Snippet Investigation of the trans-fluorine effect on the hydrolysis rate of diethyl 2-fluorocyclopropane-1,1-dicarboxylate provides synthetic access to both...
Source Web of Science
SourceID proquest
webofscience
SourceType Aggregation Database
Enrichment Source
Index Database
StartPage 2146
SubjectTerms Chemistry, Medicinal
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Science & Technology
Title trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs
URI http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000592744800011
https://www.proquest.com/docview/2463099510
Volume 11
WOS 000592744800011
WOSCitedRecordID wos000592744800011
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELWgcODSlgLqAkVGWnHCkE8n5oKqLSsk1NVKpdLeVvEXRFoSWgek8OuZ8WbZIvWAxDWJE9sZzTzbM-8R0i-yQFtrOEuiwLIk1SnLbaKZCBTgcyF5aqQXm8hGo3wyEeNuw811aZULn-gdta4V7pGfRgmPAc2ACZ3f_2GoGoWnq52ExipZiwHKYEpXNnk5ReCAbXxBpEiwuihLFxXCUXhaKIcJkLfmDqanOQkUBrPgFcz8TyDyQWf46b3d_Uw-dnCTfp_bxyZZMdUXcjSe81W3x_R6WX7ljukRHS-ZrNstctdgJGPD2QOm6Rk6pzqmZUUHrZrV0CXwJeaM_igL5FswtfOqOuBA6a-2AmjpSkdrS_0LarVo087oAGzvqUCVilJSJEapb9w2-T28uB5csk6fgaGMQsOkwp2T0KSh5ErmRcxjCSvMPANUoFFJxsZacyEKoSIBd7XMbAwOwxahhHZ5tEM-VHVlvhLKkzS0cA3WyyqRJgGvy2UkQqELlELLe-RwMc1TsH881IDx1Q9uupzoHun_-8em93O6jqnnoEEixNwD4B4J3_LYoKNIR2qAZvcNn98jGxGuxTFFMNonaxbch_lG1tVjU7q_BwDdr34eePt8BlqD8T0
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=trans-Fluorine+Effect+in+Cyclopropane%3A+Diastereoselective+Synthesis+of+Fluorocyclopropyl+Cabozantinib+Analogs&rft.jtitle=ACS+medicinal+chemistry+letters&rft.au=Veliks%2C+Janis&rft.au=Videja%2C+Melita&rft.au=Kinens%2C+Artis&rft.au=Bobrovs%2C+Raitis&rft.date=2020-11-12&rft.pub=Amer+Chemical+Soc&rft.issn=1948-5875&rft.eissn=1948-5875&rft.volume=11&rft.issue=11&rft.spage=2146&rft.epage=2150&rft_id=info:doi/10.1021%2Facsmedchemlett.0c00220&rft_id=info%3Apmid%2F33214822&rft_id=info%3Apmid%2F33214822&rft.externalDBID=n%2Fa&rft.externalDocID=000592744800011
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-5875&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-5875&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-5875&client=summon